Indium 111 Oxyquinolone Solution label

Indium 111 Oxyquinolone Solution

Indium 111 Oxyquinolone Solution Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

There is currently no usage information available for this product. We apologize for any inconvenience.

History

There is currently no drug history available for this drug.

Other Information

This preparation is supplied as a sterile, non-pyrogenic, isotonic aqueous solution with a pH range of 6.5 to 7.5 and is not for direct injection. Each milliliter contains 2 mCi at calibration time, 50μg oxyquinoline, 100μg polysorbate 80, and 6 mg of HEPES (N-2-hydroxyethyl-piperazine-N’-2-ethane sulfonic acid) buffer in 0.75% sodium chloride solution. It is intended for single use only and contains no bacteriostatic agent.

Navigate to :

Indium 111 Oxyquinolone Solution Recall

Side Effects & Adverse Reactions

FDA Safety Alerts

Manufacturer Warnings

FDA Labeling Changes

Other Information

Trending Topics

Indium 111 Oxyquinolone Solution Manufacturers

Anazaohealth Corporation
No Recall
Indium 111 Oxyquinolone Solution | Anazaohealth Corporation
The recommended adult (70kg) dose of Indium In-111 Oxyquinoline labeled autologous leukocytes is 7.4 to 18.5 MBq (200-500 μCi). Indium In-111 Oxyquinoline solution is intended for radiolabeling of autologous leukocytes. The Indium In-111 Oxyquinoline labeled autologous leukocytes are administered intravenously.

Imaging is recommended at approximately 24 hours post injection. Typically, anterior and posterior views of the chest, abdomen and pelvis should be obtained with other views as required. Aseptic procedures and a shielded syringe should be employed in the withdrawal of Indium In-111 Oxyquinoline from the vial. Similar procedures should be employed during the labeling procedure and the administration of the labeled leukocytes to the patient. The user should wear waterproof gloves during the entire procedure. The patient’s dose should be measured by a suitable radioactivity calibration system immediately before administration. At this time, the leukocyte preparation should be checked for gross clumping and red blood cell contamination
Storage and Handling
Indium In-111 Oxyquinoline solution should be stored at room temperature (15-25ºC, 59-77ºF)